Clicky

Soligenix, Inc.(SNGX)

Description: Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ' (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.


Keywords: Cancer Radiation Cancer Treatment Therapeutic Products Gastrointestinal Proteins Toxins Gastrointestinal Disease Biological Warfare Biodefense Lectins Late Stage Biopharmaceutical Castor Oil Plant

Home Page: www.soligenix.com

SNGX Technical Analysis

29 Emmons Drive
Princeton, NJ 08540
United States
Phone: 609 538 8200


Officers

Name Title
Dr. Christopher J. Schaber Ph.D. Chairman of Directors, CEO & Pres
Mr. Jonathan L. Guarino CPA, CGMA Sr. VP, CFO & Corp. Sec.
Dr. Oreola Donini Ph.D. Sr. VP & Chief Scientific Officer
Dr. Richard C. Straube M.D., MSc. Sr. VP & Chief Medical Officer
Mr. Richard L. Dunning Exec. Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 22.6189
Price-to-Sales TTM: 30.8559
IPO Date: 1987-06-15
Fiscal Year End: December
Full Time Employees: 13
Back to stocks